Share Name Share Symbol Market Type
Merck and Co Inc NYSE:MRK NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.72 -0.92% 77.45 78.655 77.15 77.81 11,591,631 00:45:00

Merck Gets FDA Expanded OK of Keytruda in Esophageal, Gastroesophageal Junction Cancer

23/03/2021 11:28am

Dow Jones News

Merck (NYSE:MRK)
Historical Stock Chart

From Mar 2021 to May 2021

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. on Tuesday said the U.S. Food and Drug Administration approved the expanded use of its cancer drug Keytruda in certain patients with locally advanced or metastatic esophageal or gastroesophageal junction cancer.

The Kenilworth, N.J., drugmaker said the approval covers Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with carcinoma that isn't amenable to surgical resection or definitive chemoradiation.

Merck said Keytruda is the first anti-PD-1 therapy in combination with chemotherapy approved for the first-line treatment of esophageal and gastroesophageal junction carcinoma, regardless of histology or PD-L1 expression.

Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, has been approved in several indications in numerous cancers.


Write to Colin Kellaher at


(END) Dow Jones Newswires

March 23, 2021 07:13 ET (11:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Merck Chart

1 Year Merck Chart

1 Month Merck Chart

1 Month Merck Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210512 03:04:37